Data from the Phase III clinical trial of ipilimumab

Just over 3 years ago, Bristol-Myers Squibb announced that treatment with ipilimumab (Yervoy) had failed to show a survival benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). For readers who may be interested, the data from this trial have finally been reported by Beer et al. in the Journal of Clinical Oncology.

2 Responses

  1. The abstract indicates that “The observed increases in progression-free survival and prostate-specific antigen response rates suggest antitumor activity in a patient subset.” What was this subset?

  2. Dear Paul:

    If you look at the original announcement from Bristol-Meyers Squibb (see link above), you will see that there was a small but statistically non-significant difference in the outcomes of the men on ipilimumab as opposed to the ones on the placebo, which does indeed “suggest antitumor activity” in a subset of patients, but as far as I am aware no one has been able to identify that subset of patients with accuracy.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: